BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22931268)

  • 1. Drotrecogin alfa (activated) in septic shock.
    Nayyar V; Solano T
    N Engl J Med; 2012 Sep; 367(10):968-9; author reply 969. PubMed ID: 22931268
    [No Abstract]   [Full Text] [Related]  

  • 2. Drotrecogin alfa (activated) in septic shock.
    Hollander JE
    N Engl J Med; 2012 Sep; 367(10):968; author reply 969. PubMed ID: 22931267
    [No Abstract]   [Full Text] [Related]  

  • 3. A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis.
    Crum NF; Groff HL; Parrish JS; Ring W
    Clin Infect Dis; 2004 Dec; 39(11):e122-3. PubMed ID: 15578351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drotrecogin alpha (activated) in septic shock after lung transplant.
    Feltracco P; Rea F; Ori C
    J Heart Lung Transplant; 2008 Jul; 27(7):815. PubMed ID: 18582817
    [No Abstract]   [Full Text] [Related]  

  • 5. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
    Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
    Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alpha (activated) in neonatal septic shock.
    Frommhold D; Birle A; Linderkamp O; Zilow E; Pöschl J
    Scand J Infect Dis; 2005; 37(4):306-8. PubMed ID: 15804668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of activated protein C in a case of paediatric septic shock.
    Verre M; Barozzi E; Piccirillo M; Tancioni F; Tiburzi S; Varano M
    Minerva Pediatr; 2005 Dec; 57(6):429-32. PubMed ID: 16402015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans.
    Bachli EB; Vavricka SR; Walter RB; Leschinger MI; Maggiorini M
    Intensive Care Med; 2003 Feb; 29(2):337. PubMed ID: 12594601
    [No Abstract]   [Full Text] [Related]  

  • 9. Drotrecogin alfa (activated) for nonmenstrual toxic shock syndrome associated with methicillin resistant Staphylococcus aureus infection.
    Haddadin DW; Samnani IQ; Moorman JP
    South Med J; 2006 Nov; 99(11):1295-6. PubMed ID: 17195430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [On activated protein C in septic shock].
    Offenstadt G
    Presse Med; 2006 Jun; 35(6 Pt 1):989; author reply 989. PubMed ID: 16783262
    [No Abstract]   [Full Text] [Related]  

  • 11. Activated protein C and septic shock: a propensity-matched cohort study*.
    Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
    Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Strongyloides stercoralis hyperinfection-associated septic shock and acute respiratory distress syndrome with drotrecogin alfa (activated) in a renal transplant recipient.
    Huston JM; Eachempati SR; Rodney JR; Cayci C; Fusco D; Mathew M; Shou J; Goldstein MJ; Kapur S; Barie PS
    Transpl Infect Dis; 2009 Jun; 11(3):277-80. PubMed ID: 19392733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) in an infant with gram-negative septic shock.
    Sajan I; Da-Silva SS; Dellinger RP
    J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Septic shock--evaluating another failed treatment.
    Wenzel RP; Edmond MB
    N Engl J Med; 2012 May; 366(22):2122-4. PubMed ID: 22616829
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of septic shock and use of drotrecogin alfa (activated) in children.
    Marraro GA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):769-72. PubMed ID: 19735218
    [No Abstract]   [Full Text] [Related]  

  • 16. "All in" for a huge pot: the PROWESS-SHOCK trial for refractory septic shock.
    Barie PS
    Surg Infect (Larchmt); 2007 Oct; 8(5):491-4. PubMed ID: 17999581
    [No Abstract]   [Full Text] [Related]  

  • 17. [Activated protein C in patients with septic shock: pro].
    Marx G
    Dtsch Med Wochenschr; 2010 Nov; 135(47):2370. PubMed ID: 21082530
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness of human recombinant activated protein C for severe sepsis and septic shock in adult and pediatric patients: randomized clinical trial versus nonrandomized study.
    Martí-Carvajal A; Gluud C
    Crit Care Med; 2013 Jul; 41(7):e139. PubMed ID: 23774363
    [No Abstract]   [Full Text] [Related]  

  • 19. Recently published papers: Sepsis--guidelines, treatment and novel approaches.
    Kalsi N; Forni LG
    Crit Care; 2008; 12(2):120. PubMed ID: 18394177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drotrecogin alfa (activated) in adults with septic shock.
    Ranieri VM; Thompson BT; Barie PS; Dhainaut JF; Douglas IS; Finfer S; Gårdlund B; Marshall JC; Rhodes A; Artigas A; Payen D; Tenhunen J; Al-Khalidi HR; Thompson V; Janes J; Macias WL; Vangerow B; Williams MD;
    N Engl J Med; 2012 May; 366(22):2055-64. PubMed ID: 22616830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.